FDG-PET is superior to amyloid PET imaging with the radiopharmaceutical florbetapir for assessing cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. By Erik L. Ridley, AuntMinnie staff writer
There’s still a long way to go with both research into Alzheimer’s disease and AI tools to help detect it, but deep-learning approaches continue to show promise. Dave Pearson | Research | AI in Healthcare
“The differences that we observed indicate the strong possibility that there are sex differences in the structural and functional connections in the brain, which may contribute to women’s increased risk for Alzheimer’s,” said Sepideh Shokouhi, at the Alzheimer’s Association International Conference in Los Angeles. Matt O'Connor | Molecular Imaging | www.healthimaging.com
ML Tool Detects Biomarker in Stroke Patients. RSNA/AAPM Symposium Focuses on Low-dose CT. Human Factors Impact Reporting of Safety Events. MRI-Based Technology Promising in Alzheimer’s. RSNA Online Series Targets Health Care Economics.
New research guidelines for classifying whether individuals have Alzheimer's disease rely heavily on the use of biomarkers from imaging scans. The new framework was published in the April issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association by Wayne Forrest, AuntMinnie.com
GCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. We aim to foster a culture of excellence through collaboration with industry experts and thought leaders to deliver better outcomes.